1-3 of 3
Xiang Fang
Close
Sort by
Journal Articles

Assessment of Durable Responses after Brexucabtagene Autoleucel (KTE-X19) in the ZUMA-2 Study in Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL)

Javier Munoz, Patrick M. Reagan, Andre H. Goy, David B. Miklos, Dan Zheng, Xiang Fang, Rhine R. Shen, Rubina Siddiqi, Ioana Kloos, Marie José Kersten, Michael Wang
Journal: Blood
Blood (2022) 140 (Supplement 1): 9320–9322.
https://doi.org/10.1182/blood-2022-158097
Published: 2022
Journal Articles

Pharmacological Profile and Clinical Outcomes of KTE-X19 By Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Exposure or Mantle Cell Lymphoma (MCL) Morphology in Patients With Relapsed/Refractory (R/R) MCL in the ZUMA-2 Trial

Michael Wang, MD, John M. Rossi, MS, Javier Munoz, MD, Andre H. Goy, MD, Frederick L. Locke, MD, Patrick M. Reagan, MD, Caron A. Jacobson, MD, Brian T. Hill, MD, Houston Holmes, Samantha Jaglowski, MD MPH, Weimin Peng, PhD, Lianqing Zheng, PhD, Xiang Fang, PhD, Allen Xue, PhD, Ioana Kloos, MD, Adrian Bot, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 29.
https://doi.org/10.1182/blood-2020-136831
Published: 2020
Journal Articles

Inhibiting Translation as a Novel Strategy to Target Multiple Myeloma

William Roman, BSc, Regina Cencic, PhD, Xiang-Fang Huang, John Porco, PhD, Jerry Pelletier, PhD, Chaim Shustik, MD, Michael Sebag, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 2995.
https://doi.org/10.1182/blood.V116.21.2995.2995
Published: 2010